Free tool
FAERS Monitor: Lumason
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203684 or its brand name (Lumason, Sulfur Hexafluoride Lipid-Type A Microspheres). Reports on generic versions are filed under their own applications.
Reports
1,980
Serious
1,360
69% of reports
Hospitalization
482
Death reported
101
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea335
- nausea277
- anaphylactic reaction252
- hyperhidrosis231
- flushing196
- hypotension168
- dizziness162
- feeling hot157
- hypersensitivity136
- erythema135
- blood pressure decreased125
- unresponsive to stimuli123
- pruritus120
- paraesthesia119
- cardiac arrest116
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 17 |
| 2013 | 9 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 22 |
| 2017 | 34 |
| 2018 | 60 |
| 2019 | 69 |
| 2020 | 72 |
| 2021 | 129 |
| 2022 | 215 |
| 2023 | 448 |
| 2024 | 280 |
| 2025 | 277 |
| 2026 | 346 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,179 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| unresponsive to stimuliSignal | 123 | 50.9 | 42.8 | 5,941 |
| anaphylactic reactionSignal | 252 | 48.7 | 43.3 | 11,694 |
| feeling hotSignal | 157 | 27.3 | 23.5 | 3,948 |
| flushingSignal | 196 | 20.5 | 18.0 | 3,630 |
| blood pressure decreasedSignal | 125 | 20.0 | 16.9 | 2,242 |
| hyperhidrosisSignal | 231 | 19.1 | 16.9 | 3,957 |
| cardiac arrestSignal | 116 | 14.9 | 12.5 | 1,499 |
| hypotensionSignal | 168 | 8.9 | 7.7 | 1,181 |
| paraesthesiaSignal | 119 | 8.0 | 6.8 | 732 |
| hypersensitivitySignal | 136 | 7.8 | 6.6 | 804 |
| erythemaSignal | 135 | 7.0 | 5.9 | 692 |
| dyspnoeaSignal | 335 | 6.3 | 5.7 | 1,525 |
| nauseaSignal | 277 | 3.7 | 3.3 | 569 |
| dizzinessSignal | 162 | 3.5 | 3.0 | 286 |
| pruritusSignal | 120 | 3.3 | 2.8 | 195 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.